FigureĀ 2.
Distribution of AML ontogeny subtypes in each genomic class. The width of each bar indicates the number of patients. MR indicates patients with AML with MR gene mutations (including ASXL1, BCOR, EZH2, STAG2, SF3B1, SRSF2, ZRSR2, and U2AF1, but no RUNX1 mutations). MR-RUNX1 indicates patients with AML with both MR gene and RUNX1 gene mutations. RUNX1 indicates patients with AML with RUNX1 but no MR gene mutations. MR/RUNX1 indicates patients with AML with MR and/or RUNX1 gene mutations. NOS indicates patients with AML with mutations detected but cannot be assigned to a well-defined entity. NEG indicates patients with AML with no mutations or rearrangements detected.

Distribution of AML ontogeny subtypes in each genomic class. The width of each bar indicates the number of patients. MR indicates patients with AML with MR gene mutations (including ASXL1, BCOR, EZH2, STAG2, SF3B1, SRSF2, ZRSR2, and U2AF1, but no RUNX1 mutations). MR-RUNX1 indicates patients with AML with both MR gene and RUNX1 gene mutations. RUNX1 indicates patients with AML with RUNX1 but no MR gene mutations. MR/RUNX1 indicates patients with AML with MR and/or RUNX1 gene mutations. NOS indicates patients with AML with mutations detected but cannot be assigned to a well-defined entity. NEG indicates patients with AML with no mutations or rearrangements detected.

Close Modal

or Create an Account

Close Modal
Close Modal